This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wacker, B. Articles by Cagnoni, P. J. Search for Related Content PubMed PubMed Citation Articles by Wacker, B. Articles by Cagnoni, P. J.

Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies

Authors' Affiliation: OSI Pharmaceuticals, Boulder, Colorado

Requests for reprints: Bret Wacker, OSI Pharmaceuticals, 2860 Wilderness Place, Boulder, CO 80301. Phone: 303-546-7638; Fax: 303-546-7889; E-mail: bwacker{at}osip.com.

Purpose: Data from two large phase III studies were analyzed to characterize the correlation between the occurrence of rash during treatment with the epidermal growth factor receptor inhibitor erlotinib and improved clinical outcomes.

Experimental Design: Overall survival, progression-free survival (PFS), and tumor response were compared between patients in a rash-evaluable subset who did or did not develop rash in National Cancer Institute of Canada Clinical Trials Group Studies BR.21 (single agent in non–small-cell lung cancer, n = 444 in erlotinib group and n = 229 in placebo group) and PA.3 (combination with gemcitabine in pancreatic cancer, n = 254 in erlotinib plus gemcitabine group and n = 245 in placebo plus gemcitabine group).

Results: Presence of rash strongly correlated with overall survival in both studies. In Study BR.21, these correlations increased with rash severity grade: grade 1 versus no rash [hazard ratio (HR), 0.41, P < 0.001] and grade 2 versus no rash (HR, 0.29, P < 0.001). Similar results were observed for PFS. Disease control (complete response + partial response + stable disease) seemed to increase with the presence and severity of rash. In Study PA.3, grade 2 rash (but not grade 1) strongly correlated with overall survival improvement: grade 2 versus no rash (HR, 0.47, P < 0.001). Similarly, grade 2 rash was strongly correlated with improvements in PFS and disease control.

Conclusions: Physicians and patients should view rash development as a positive event indicative of greater likelihood of clinical benefit. Further studies are required to identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.

This article has been cited by other articles:

				M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer Ann. Onc., June 24, 2009; (2009) mdp202v1. [Abstract] [Full Text] [PDF]

				J. Bergh Quo Vadis With Targeted Drugs in the 21st Century? J. Clin. Oncol., January 1, 2009; 27(1): 2 - 5. [Full Text] [PDF]

				A. Jatoi and P. L. Nguyen Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy Oncologist, November 1, 2008; 13(11): 1201 - 1204. [Abstract] [Full Text] [PDF]

				R. I. Jakacki, M. Hamilton, R. J. Gilbertson, S. M. Blaney, J. Tersak, M. D. Krailo, A. M. Ingle, S. D. Voss, J. E. Dancey, and P. C. Adamson Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study J. Clin. Oncol., October 20, 2008; 26(30): 4921 - 4927. [Abstract] [Full Text] [PDF]

				C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? Oncologist, September 1, 2008; 13(9): 933 - 944. [Abstract] [Full Text] [PDF]

				P. A. Gerber, E. Enderlein, and B. Homey The Koebner-Phenomenon in Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Adverse Effects J. Clin. Oncol., June 1, 2008; 26(16): 2790 - 2792. [Full Text] [PDF]

				F. Ciardiello and G. Tortora EGFR Antagonists in Cancer Treatment N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174. [Full Text] [PDF]

				R. Perez-Soler Erlotinib: Recent Clinical Results and Ongoing Studies in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4589s - 4592s. [Abstract] [Full Text] [PDF]